Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $81.2 (market cap $2.06B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 61.9× Global X Robo Global Robotics & Automation ETF's market cap, and Global X Robo Global Robotics & Automation ETF is more actively traded (148,111 versus 1,487,944). Which is the better fit depends on your goals — on Pluang, investors hold Global X Robo Global Robotics & Automation ETF for 36 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| ROBO | VRTX | |
|---|---|---|
Market Cap | $2.06B | $127.55B |
Volume | 148,111 | 1,487,944 |
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $557.96 |
52-Week Low | $63.04 | $407.37 |
Typical Hold Time | 36 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO trades at $81.82, down 1.89% today amid mixed technical signals. The overall technical outlook remains bullish with strong moving average support, though oscillators show bearish momentum with RSI levels above 79 indicating potential overbought conditions. Recent news highlights accelerating robotics adoption across manufacturing, healthcare, and military applications, with Q2 2026 earnings showing broadening demand for physical AI technologies.
The robotics ETF offers diversified exposure to a sector benefiting from labor shortages and AI infrastructure growth. Key risks include valuation concerns amid rapid sector expansion and potential market volatility. Analyst coverage remains positive on long-term robotics adoption trends, though current technical indicators suggest near-term consolidation may be needed after recent gains.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
